Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GSK586529 capsules
GSK586529 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Subjects receiving treatment in cohort 1 | EXPERIMENTAL | Subjects will receive one of the following sequences; ABDF,BADF, BDAF or BDFA (A=Placebo, B= GSK586529 dose 1 (3 milligrams), D = GSK586529 dose 3, F = GSK586529 dose 5). |
| Subjects receiving treatment in cohort 2 | EXPERIMENTAL | Subjects will receive one of the following sequences; ACEG,CAEG, CEAG or CEGA (A = Placebo, C= GSK586529 dose 2, E = GSK586529 dose 4, G = GSK586529 dose 6) |
| Name | Type | Description |
|---|---|---|
| GSK586529 capsules | DRUG | GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams. |
| GSK586529 tablets | DRUG | GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams. |
| Placebo | DRUG | Placebo tablets and capsules will be provided to subjects. |
Inclusion Criteria: * Healthy males aged 18-45 years, inclusive. * Healthy subjects, defined as individuals who are free from clinically significant illness or disease as determined by their (and familial) medical and psychiatric history, physical examination, laboratory studies, and other tests. *...
GSK586529 is an investigational small molecule developed by GSK plc for depressive disorder and anxiety disorders. It has been studied in a first-time-in-human Phase 1 trial in healthy volunteers. It is not an approved medicine and remains in clinical development.
GSK586529 is being developed for depressive disorder and anxiety disorders. The only reported clinical study enrolled healthy volunteers rather than patients, so the compound has not yet been evaluated for treatment effect in people with these conditions.
GSK586529 is developed by GSK plc, which trades under the ticker GSK. The company sponsored the first-time-in-human study of the compound, which was conducted in the United Kingdom.
GSK586529 is in Phase 1 development. One Phase 1 first-time-in-human study has been completed, and no active trials are currently listed. The drug is investigational and has not been approved for any indication.
GSK586529 has been studied in one completed Phase 1 trial, NCT00703547, titled A First Time in Human Study of GSK586529 in Healthy Volunteers. It enrolled 21 male healthy volunteers aged 18 years and older in the United Kingdom and used a controlled, randomized design.
Yes. GSK586529 capsules is another name used for GSK586529, the investigational small molecule from GSK plc. Both names refer to the same compound studied in the Phase 1 trial NCT00703547 for depressive disorder and anxiety disorders.